Journals / Turkish Journal of Urology / 2022 / Cilt: 48 - Sayı: 1

Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma

Pages
58–63
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We suggested that betulinic acid with its apoptotic effect on RCC line and nontoxic effect on healthy cell line and the effects on AKT/mTOR pathway may be a potential anticancer drug promising for future studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Renal cancer is the most lethal among urological cancer.
📊
Key Findings & Data:We aimed to determine the apoptotic effect of betulinic acid and its effects on expressions of apoptosisassociated genes AKT-1 and mTOR in RCC cells.
💡
Conclusion & Impact:Conclusion: We suggested that betulinic acid with its apoptotic effect on RCC line and nontoxic effect on healthy cell line and the effects on AKT/mTOR pathway may be a potential anticancer drug promising for future studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Renal cancer is the most lethal among urological cancer. Treatments of renal cell carcinoma (RCC) may be possible by immune checkpoint inhibitors and drug treatment targeting different molecules. We aimed to determine the apoptotic effect of betulinic acid and its effects on expressions of apoptosisassociated genes AKT-1 and mTOR in RCC cells. Material and methods: In this study, we investigated the apoptotic activity of betulinic acid in CAKI-2 cell line and its effect on AKT-1 and mTOR gene expression levels. In order to do so, following analyses were conducted: WST-1 to identify the toxic effect of betulinic acid, Caspase-3/BCA to detect caspase enzyme activity, Annexin-V and ELISA to determine for apoptotic effect, and finally, real-time PCR for expression levels of AKT-1 and mTOR. Results: Our study showed that different concentrations of betulinic acid induced apoptosis in renal cancer; however, no effect was observed in healthy cells. In gene expression analysis, there was statistically significant decrease in AKT-1 expression level while increasing mTOR expression level. Conclusion: We suggested that betulinic acid with its apoptotic effect on RCC line and nontoxic effect on healthy cell line and the effects on AKT/mTOR pathway may be a potential anticancer drug promising for future studies.

🔖

Cite This Article

ATAŞ, M. N., ERTUĞRUL, B., İPLİK, E. S., ÇAKMAKOĞLU, B., ERGEN, H. A. (2022). Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma. Turkish Journal of Urology, Cilt: 48 - Sayı: 1, 58–63. https://ajindex.com/articles/413232

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74-84. [CrossRef] 2. Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer. Semin Cancer Biol. 2013;23(1):46-55. [CrossRef] 3. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894-906. [CrossRef] 4. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009. [CrossRef] 5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [CrossRef] 6. Zaman S, Wang R, Gandhi V. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 2014;55(9):1980- 1992. [CrossRef] 7. Sa´nchez-Gastaldo A, Kempf E, Gonza´lez del Alba A, Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017;60:77-89. [CrossRef 8. Guo H, German P, Bai S, et al. The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics. 2015;42(7):343-353. [Cross- Ref] 9. Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol BioSyst. 2015;11(7):1946-1954. [CrossRef] 10. O’Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKTmTOR inhibition in cancer immunotherapy redux. Semin Cancer Biol. 2018;48:91-103. [CrossRef] 11. Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs. 2009;20(10):880-892. [CrossRef] 12. Zhou M, Zhang RH, Wang M, Xu GB, Liao SG. Prodrugs of triterpenoids and their derivatives. Eur J Med Chem. 2017;131:222- 236. [CrossRef] 13. Ren Y, Kinghorn A. Natural product triterpenoids and their semisynthetic derivatives with potential anticancer activity. Planta Med. 2019;85(11-12):802-814. [CrossRef] 14. Xu F, Huang X, Wu H, Wang X. Beneficial health effects of lupenone triterpene: A review. Biomed Pharmacother. 2018;103:198- 203. [CrossRef] 15. Castro MJ, Careaga VP, Sacca PA, Faraoni MB, Murray AP, Calvo JC. Lupane triterpenoids and new derivatives as antiproliferative agents against prostate cancer cells. Anticancer Res. 2019;39(7):3835-3845. [CrossRef] 16. Sun Y, Gao LL, Tang MY, Feng BM, Pei YH, Yasukawa K. Triterpenoids from euphorbia maculata and their anti-inflammatory effects. Molecules. 2018;23(9):2112. [CrossRef] 17. Khwaza V, Oyedeji OO, Aderibigbe BA. Antiviral activities of oleanolic acid and its analogues. Molecules. 2018;23(9):2300. [